Vermillion Expects $2M Payment from Bio-Rad Following Patent Re-Issue

Nov 05, 2007

NEW YORK (GenomeWeb News) – The US Patent and Trademark Office has re-issued a patent covering SELDI mass spec-related technology to Vermillion, formerly called Ciphergen, that entitles the diagnostics developer to a $2 million payment from Bio-Rad Laboratories, Vermillion said today.

Bio-Rad agreed to the payment when it bought Vermillion’s proteomics tools business a year ago for $20 million in cash and a $3 million investment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

Main menu